P
P

Pfizer


Balita

New York Times business news - May 27

May 27 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy. - Carl Icahn gets only 1 percent of McDonald's MCD.N investors to support his campaign on pigs, the activist investor had nominated two directors to the company’s board as part of
B
P

New York Times business news - May 24

May 24 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy. - JPMorgan Chase & Co JPM.N expects to make money from rising interest rates and bumpy markets, market volatility will increase revenue from trading, while borrowers will be shellin
J
P
S

Wall Street rallies to higher close boosted by banks, big tech

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window) (Updates to closing bell) By Stephen Culp NEW YORK, May 23 (Reuters) - U.S. stocks ended higher on Monday as gains from banks and a rebound in megacap market leaders supported a broad-based rally following Wall Street's longest streak of wee
A
B
J
M
P
U
U

Wall Street rebounds with assist from banks, big tech

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window) * JPMorgan leads banks higher on upbeat interest income outlook * Broadcom shares fall on potential VMware buyout * Indexes up: Dow 1.98%, S&P 1.73%, Nasdaq 1.26% By Stephen Culp NEW YORK, May 23 (Reuters) - Wall Street rallied on Monday as
A
B
J
P
U
U

U.S. FDA sets June meeting dates for Moderna, Pfizer small children 19 vaccines

WASHINGTON, May 23 (Reuters) - The U.S. Food and Drug Administration set June 14-15 as the new meeting date to review Moderna Inc's emergency authorization request for its COVID-19 vaccine for children aged 6 months to 5 years and Pfizer Inc's vaccine for those aged 6 months through 4 years. The new dates for our pediatric COVID-19 vaccine advisory
P

Wall Street ends mixed after punishing week

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window) * Ross Stores plunges after cutting 2022 forecast * S&P 500 +0.01%, Nasdaq -0.30%, Dow +0.03% (Updates with details at end of session) By Noel Randewich and Amruta Khandekar May 20 (Reuters) - Wall Street ended mixed on Friday after a volati
G
N
P
T
R
U
U

Switzerland buys Pfizer's 19 antiviral Paxlovid

BERLIN, May 20 (Reuters) - Switzerland signed a contract to buy Pfizer's anti-viral drug Paxlovid to treat Covid-19, it said on Friday. The European country said it had signed a contract to buy 12,000 packages and first treatments for certain at-risk patients would start this month. Reporting by Kirsti Knolle, Editing by Miranda Murray
P

British Business - May 11

May 11 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - Tesla Inc's TSLA.O factory in Shanghai has scaled back production after being hit by supply chain problems, only three weeks after work restarted there. Link - Pf
P
T
T
E

Evonik to invest 8 bln eur by 2030 in high-margin businesses -CEO

* Around 4 bln eur to be invested in Germany * Russia business to come to a standstill * Baby business, C4 unit, Luelsdorf site up for sale BERLIN, May 10 (Reuters) - German chemicals company Evonik EVKn.DE plans to invest 8 billion euros ($8.45 billion) by 2030 to boost growth in its smart materials, specialty additives and nutrition & care units,
P
V

BioNTech's Q1 vaccine sales triple but it still flags full-year decline

FRANKFURT, May 9 (Reuters) - BioNTech's 22UAy.DE first-quarter sales and earnings more than tripled thanks to demand for the COVID-19 vaccine it developed with Pfizer PFE.N , but the German biotech firm is still forecasting a full-year decline in vaccine sales. Quarterly revenues more than tripled from a year earlier to 6.37 billion euros ($6.73 bi
P

BioNTech posts tripled Q1 vaccine sales but still flags full-year decline

FRANKFURT, May 9 (Reuters) - BioNTech 22UAy.DE said first-quarter sales and earnings more than tripled thanks to demand for the COVID-19 vaccine it developed with Pfizer PFE.N , but the German biotech firm reaffirmed its forecast for a full-year decline in vaccine sales. First-quarter revenues more than tripled from the year-earlier period, to 6.37
P

EU regulator hopes to approve COVID variant-adapted vaccines by autumn

May 5 (Reuters) - The European Union's drug regulator said on Thursday it hoped to have vaccines adapted to address coronavirus variants, such as Omicron, approved by September. "Our priority is to ensure that adaptive vaccines are possibly approved by September at the latest to be ready for the rollout of new immunisation campaigns in the EU in th
P

Wall St Week Ahead-Rocky stock market faces Fed test with eyes on tightening plans

By Lewis Krauskopf NEW YORK, April 29 (Reuters) - A volatile stock market faces a critical test next week, when the U.S. Federal Reserve is expected to raise interest rates and give more insight on its plans for tightening monetary policy to fight surging inflation. Worries over an increasingly hawkish Fed have helped drag the benchmark S&P 500 ind
P
S
U

Wall St Week Ahead-Rocky stock market faces Fed test with eyes on tightening plans

(Updates with further market data) By Lewis Krauskopf NEW YORK, April 29 (Reuters) - A volatile stock market faces a critical test next week, when the U.S. Federal Reserve is expected to raise interest rates and give more insight on its plans for tightening monetary policy to fight surging inflation. Worries over an increasingly hawkish Fed have he
A
P
S
U

Wall St Week Ahead-Rocky stock market faces Fed test with eyes on tightening plans

By Lewis Krauskopf NEW YORK, April 29 (Reuters) - A volatile stock market faces a critical test next week, when the U.S. Federal Reserve is expected to raise interest rates and give more insight on its plans for tightening monetary policy to fight surging inflation. Worries over an increasingly hawkish Fed have helped drag the benchmark S&P 500 ind
P
S
U

Wall Street Journal - April 27

April 27 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - U.S. Vice President Kamala Harris tested positive for COVID-19 on Tuesday, her press secretary, Kirsten Allen, said. on.wsj.com/3EP4CCf - Mattel Inc MAT.O has held talks with private-equi
M
P

India to face more power cuts due to coal shortage, soaring demand

* India FY23 power output seen 15.2% up, coal-fired power over 17% Coal trains to utilities from April 1-6 at 379/day vs 453 needed Coal India FY23 supply target to power sector 565 mln T * Total FY23 local coal requirement at 760 mln T By Sudarshan Varadhan CHENNAI, April 12 (Reuters) - India is likely to face more power cuts this year as utilitie
P

India to face more power cuts due to coal shortage, soaring demand

* India FY23 power output seen 15.2% up, coal-fired power over 17% Coal trains to utilities from April 1-6 at 379/day vs 453 needed Coal India FY23 supply target to power sector 565 mln T * Total FY23 local coal requirement at 760 mln T By Sudarshan Varadhan CHENNAI, April 12 (Reuters) - India is likely to face more power cuts this year as utilitie
P

UK Stocks-Factors to watch on April 12

April 12 (Reuters) - Britain's FTSE 100 index .FTSE is seen opening lower on Tuesday, with futures FFIc1 down 0.59%. * EASYJET: Britain's easyJet EZJ.L said it had outperformed its first-half expectations despite the challenges of COVID-19 and rising fuel prices, with capacity ramping up to reach 80% of pre-pandemic levels in March and a recovery i
E
M
P
P
P
U
P

UK Stocks-Factors to watch on April 12

April 12 (Reuters) - Britain's FTSE 100 index .FTSE is seen opening lower on Tuesday, with futures FFIc1 down 0.78%. * PARKER-HANNIFIN-MEGGITT: U.S. engineering and aerospace group Parker-Hannifin PH.N on Monday won EU antitrust approval for its 6.3-billion-pound ($8.2 billion) planned acquisition of Britain's Meggitt MGGT.L after pledging to sell
E
M
P
P
U
P



Kundisyon

Mga Patok na Assets

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Gumagamit kami ng cookies para mabigyan ka ng mahusay na karanasan sa aming website. Magbasa pa o palitan ang iyong cookie settings.

Babala sa Risk: Maaaring malugi ang iyong kapital. Maaaring hindi nababagay sa lahat ang mga produktong naka-leverage. Mangyaring isaalang-alang ang aming Pahayag sa Risk.